Primary Radiotherapy for Carcinoma of the Retromolar Trigone: A Useful Alternative to Surgery

Bayman, N.A.; Sykes, A.J.; Bonington, S.; Blackburn, T.; Patel, M.; Swindell, R.; Slevin, N.J.

doi:10.1016/j.clon.2009.10.017

« Previous Next »Clinical Oncology
Volume 22, Issue 2 , Pages 119-124, March 2010

Primary Radiotherapy for Carcinoma of the Retromolar Trigone: A Useful Alternative to Surgery

N.A. Bayman
- Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
- Author for correspondence: N.A. Bayman, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 6HX, UK. Tel: +44-161-446-3337.
A.J. Sykes
- Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
S. Bonington
- Department of Radiology, The Christie NHS Foundation Trust, Manchester, UK
T. Blackburn
- Department of Maxillofacial Surgery, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
M. Patel
- Department of Maxillofacial Surgery, South Manchester University Hospitals NHS Foundation Trust, Manchester, UK
R. Swindell
- Department of Medical Statistics, The Christie NHS Foundation Trust, Manchester, UK
N.J. Slevin
- Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK

Received 6 August 2009; received in revised form 28 September 2009; accepted 13 October 2009.

Abstract

Aims

Squamous cell carcinoma of the retromolar trigone is uncommon. The standard initial treatment is primary surgery, which usually involves microvascular reconstruction with a composite flap. Some patients are considered unsuitable for this procedure. This retrospective study examined the outcome and toxicity for patients with squamous cell carcinoma of the retromolar trigone treated with definitive radiotherapy in a single centre.

Materials and methods

Between 1991 and 2000, 43 patients were treated with definitive radiotherapy with a median dose of 50Gy in 16 fractions over 21 days. Hospital case notes and radiotherapy records were analysed.

Results

The median age was 66 years (range 39–84 years). Nodal disease was evident in 13 (30.2%) patients. Twenty-one patients (51.2%) had stage I/II disease and 20 patients (48.8%) had stage III/IV disease. After a median follow-up of 59 months, 13 (30.2%) patients were alive and well, nine (20.9%) patients had died of an intercurrent illness and 21 (48.8%) had died of their disease. Five-year locoregional control was 46.5% (95% confidence interval 29.7–61.7), cause-specific survival was 45.7% (95% confidence interval 29.1–60.8) and overall survival was 30.9% (95% confidence interval 17.5–46.3). Osteoradionecrosis was documented in two patients.

Discussion

This hypofractionated regimen is convenient for this patient population and produced comparable outcomes to longer fractionation schedules without an increase in late toxicity.

Key words: Oral cavity, radiotherapy, retromolar trigone, squamous cell carcinoma